CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-03-14 | Yu Yong VP, Clinical Trial Operations | Grant or award | +11,557 | 17,718 | ||
| 2024-03-14 | Ryder Sean General Counsel | Grant or award | +9,270 | 22,778 | ||
| 2024-03-14 | Jewett Caroline Head of Quality | Grant or award | +3,612 | 25,890 | ||
| 2024-02-19 | Zindrick Thomas President and CEO | Grant or award | +8,320 | 22,971 | ||
| 2024-02-19 | Zak Lourie S. Chief Financial Officer | Grant or award | +1,220 | 32,470 | ||
| 2024-02-19 | Smalling Ralph Head of Regulatory | Grant or award | +616 | 13,931 | ||
| 2024-02-19 | Cappello Joseph VP, Pharmaceutical Development | Grant or award | +3,661 | 9,396 | ||
| 2024-02-19 | Yu Yong VP, Clinical Trial Operations | Grant or award | +3,661 | 6,161 | ||
| 2024-02-19 | Ryder Sean General Counsel | Grant or award | +2,936 | 13,508 | ||
| 2024-02-19 | Jewett Caroline Head of Quality | Grant or award | +1,143 | 22,278 |
Page 9 of 9 · 170 trades